TY  - JOUR
AU  - Salavert, Miguel
AU  - Cobo, Javier
AU  - Pascual, Álvaro
AU  - Aragón, Belén
AU  - Maratia, Stefano
AU  - Jiang, Yiling
AU  - Aceituno, Susana
AU  - Grau, Santiago
PY  - 2018
DO  - 10.1007/s12325-018-0813-y
UR  - http://hdl.handle.net/10668/13097
T2  - Advances in therapy
AB  - Clostridium difficile infection (CDI) is the major cause of infectious nosocomial diarrhoea and is associated with considerable morbidity, mortality and economic impact. Bezlotoxumab administered in combination with standard of care (SoC) antibiotic...
LA  - en
KW  - Bezlotoxumab
KW  - Clostridium difficile infection
KW  - Cost-effectiveness
KW  - Aged
KW  - Anti-Bacterial Agents
KW  - Antibodies, Monoclonal
KW  - Antibodies, Neutralizing
KW  - Broadly Neutralizing Antibodies
KW  - Clostridioides difficile
KW  - Clostridium Infections
KW  - Cost-Benefit Analysis
KW  - Drug Therapy, Combination
KW  - Female
KW  - Health Care Costs
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Secondary Prevention
KW  - Spain
KW  - Standard of Care
KW  - Survival Analysis
KW  - Treatment Outcome
TI  - Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.
TY  - research article
VL  - 35
ER  -